drugset / Trial / NCT05947890
Evaluating the Safety and Immunogenicity of MTBVAC
Phase 2
Recruiting
276 enrolled
HIV Vaccine Trials Network
Biofabri, S.L · collabFred Hutchinson Cancer Center · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
Timeline
- Start
- 2024-01-30
- Primary completion
- 2027-04-05
- Completion
- 2027-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCG | Vaccine | 0.1 ml | Other |
| Subject | MTBVAC | Vaccine | 0.1 ml | Other |